DE69712100D1 - Valproinsäure enthaltende mikrosphären für orale verabreichung - Google Patents

Valproinsäure enthaltende mikrosphären für orale verabreichung

Info

Publication number
DE69712100D1
DE69712100D1 DE69712100T DE69712100T DE69712100D1 DE 69712100 D1 DE69712100 D1 DE 69712100D1 DE 69712100 T DE69712100 T DE 69712100T DE 69712100 T DE69712100 T DE 69712100T DE 69712100 D1 DE69712100 D1 DE 69712100D1
Authority
DE
Germany
Prior art keywords
oral administration
acid containing
valproic acid
containing microspheres
microspheres
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69712100T
Other languages
English (en)
Other versions
DE69712100T2 (de
Inventor
Christian Langlois
Jean-Yves Lanne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Application granted granted Critical
Publication of DE69712100D1 publication Critical patent/DE69712100D1/de
Publication of DE69712100T2 publication Critical patent/DE69712100T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69712100T 1996-10-07 1997-10-03 Valproinsäure enthaltende mikrosphären für orale verabreichung Expired - Lifetime DE69712100T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9612201A FR2754177B1 (fr) 1996-10-07 1996-10-07 Microspheres pharmaceutiques d'acide valproique pour administration orale
PCT/FR1997/001762 WO1998015268A1 (fr) 1996-10-07 1997-10-03 Microspheres pharmaceutiques d'acide valproique pour administration orale

Publications (2)

Publication Number Publication Date
DE69712100D1 true DE69712100D1 (de) 2002-05-23
DE69712100T2 DE69712100T2 (de) 2002-11-28

Family

ID=9496427

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69712100T Expired - Lifetime DE69712100T2 (de) 1996-10-07 1997-10-03 Valproinsäure enthaltende mikrosphären für orale verabreichung

Country Status (40)

Country Link
US (3) US20020001598A1 (de)
EP (1) EP0956010B1 (de)
JP (1) JP3523270B2 (de)
KR (1) KR100334687B1 (de)
CN (1) CN100367945C (de)
AR (1) AR013613A1 (de)
AT (1) ATE216228T1 (de)
AU (1) AU731235B2 (de)
BR (1) BR9712268A (de)
CA (1) CA2267096C (de)
CO (1) CO4900080A1 (de)
CZ (1) CZ288876B6 (de)
DE (1) DE69712100T2 (de)
DK (1) DK0956010T3 (de)
DZ (1) DZ2316A1 (de)
EE (1) EE03744B1 (de)
EG (1) EG24070A (de)
ES (1) ES2174293T3 (de)
FR (1) FR2754177B1 (de)
HK (1) HK1021939A1 (de)
HR (1) HRP970537B1 (de)
HU (1) HU225103B1 (de)
ID (1) ID24596A (de)
IL (1) IL128745A (de)
IS (1) IS1985B (de)
ME (1) ME00664B (de)
MY (1) MY120521A (de)
NO (1) NO325723B1 (de)
NZ (1) NZ334399A (de)
PL (1) PL190105B1 (de)
PT (1) PT956010E (de)
RS (1) RS49602B (de)
RU (1) RU2177315C2 (de)
SI (1) SI0956010T1 (de)
SK (1) SK282113B6 (de)
TR (1) TR199900789T2 (de)
TW (1) TW508251B (de)
UY (1) UY24738A1 (de)
WO (1) WO1998015268A1 (de)
ZA (1) ZA978954B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1187601E (pt) 1999-06-07 2005-11-30 Altana Pharma Ag Nova forma de preparacao e a administracao compreendendo um inibidor da bomba de protoes instavel em meio acido
US20060223888A1 (en) * 2002-12-16 2006-10-05 Abbott Frank S Valproic acid analogues and pharmaceutical composition thereof
TWI356036B (en) * 2004-06-09 2012-01-11 Smithkline Beecham Corp Apparatus and method for pharmaceutical production
JP2008512386A (ja) * 2004-09-07 2008-04-24 オーファン メディカル，インコーポレイティド 改良型ｇｈｂ組成物
US9149433B2 (en) * 2004-11-30 2015-10-06 Basf Corporation Method for formation of micro-prilled polymers
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
US8992422B2 (en) 2006-03-23 2015-03-31 Ethicon Endo-Surgery, Inc. Robotically-controlled endoscopic accessory channel
CN101543631B (zh) * 2008-03-28 2012-01-11 沈阳兴齐制药有限公司 含蜂蜡的微球基质、含有它的药物组合物及其用途
KR101330889B1 (ko) * 2009-05-12 2013-11-18 (주)아모레퍼시픽 탈모 방지 또는 육모 촉진을 위한 조성물
AU2014350208B2 (en) * 2013-11-13 2017-09-07 Tillotts Pharma Ag Multi-particulate drug delivery system
CN104013596A (zh) * 2014-05-16 2014-09-03 安士制药（中山）有限公司 一种丙戊酸软胶囊及其制备方法
CN105456217A (zh) * 2014-08-27 2016-04-06 捷思英达医药技术（上海）有限公司 一种双丙戊酸钠缓释剂组合物及其制备方法
KR102463794B1 (ko) 2017-08-24 2022-11-04 미쓰이 가가쿠 가부시키가이샤 전지용 비수 전해액 및 리튬 이차 전지
KR20200035095A (ko) 2017-08-24 2020-04-01 미쓰이 가가쿠 가부시키가이샤 리튬 이차 전지 및 비수 전해액
FR3087445B1 (fr) * 2018-10-19 2021-12-17 Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic Composition lipidique pour l'encapsulation d'une substance active et permettant le controle de la vitesse de liberation de ladite substance active
CN111012753A (zh) * 2020-01-07 2020-04-17 仁和堂药业有限公司 一种提高丙戊酸钠片剂稳定性的方法
CN112274499A (zh) * 2020-11-16 2021-01-29 仁和堂药业有限公司 一种提高丙戊酸钠片剂稳定性的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2293974A1 (fr) * 1973-03-02 1976-07-09 Kaltenbach Roger Procede et dispositif pour la granulation reguliere de divers produits
US5212326A (en) * 1979-08-20 1993-05-18 Abbott Laboratories Sodium hydrogen divalproate oligomer
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
IL72381A (en) * 1983-07-20 1988-03-31 Sanofi Sa Pharmaceutical composition based on valproic acid
US5185159A (en) * 1983-07-20 1993-02-09 Sanofi Pharmaceutical composition based on valproic acid and a process for preparing it
US4913906B1 (en) * 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
JP2893191B2 (ja) * 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
EP0418596A3 (en) * 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
FR2657257B1 (fr) * 1990-01-19 1994-09-02 Rhone Poulenc Sante Procede de preparation de medicaments sous forme de perles.
TW209174B (de) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
JP3426230B2 (ja) * 1991-05-20 2003-07-14 アベンティス・ファーマスーティカルズ・インコーポレイテッド 複数層の制御放出処方剤
FR2682677A1 (fr) * 1991-10-17 1993-04-23 Sanofi Elf Complexe forme de l'acide propyl-2 pentene-2 ouique (e) et de son sel de sodium, sa preparation et compositions pharmaceutiques le contenant.
US6287598B1 (en) * 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
US5690959A (en) * 1993-05-29 1997-11-25 Smithkline Beecham Corporation Pharmaceutical thermal infusion process
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
US5916910A (en) * 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці

Also Published As

Publication number Publication date
US20030157177A1 (en) 2003-08-21
HRP970537A2 (en) 1998-08-31
CZ288876B6 (cs) 2001-09-12
SK282113B6 (sk) 2001-11-06
CZ121199A3 (cs) 1999-08-11
IS4996A (is) 1999-03-11
JP2000504038A (ja) 2000-04-04
YU17899A (sh) 2000-03-21
US20060263437A1 (en) 2006-11-23
CA2267096C (fr) 2003-09-16
KR20000048828A (ko) 2000-07-25
SK36499A3 (en) 2000-12-11
HUP9903855A2 (hu) 2000-05-28
DE69712100T2 (de) 2002-11-28
RU2177315C2 (ru) 2001-12-27
HU225103B1 (en) 2006-06-28
EE9900140A (et) 1999-12-15
ZA978954B (en) 1999-04-07
ID24596A (id) 2000-07-27
MY120521A (en) 2005-11-30
BR9712268A (pt) 1999-08-31
ME00664B (me) 2007-06-04
PL190105B1 (pl) 2005-10-31
CN100367945C (zh) 2008-02-13
NO991613D0 (no) 1999-04-06
PT956010E (pt) 2002-08-30
NO325723B1 (no) 2008-07-07
TW508251B (en) 2002-11-01
NZ334399A (en) 2000-05-26
ES2174293T3 (es) 2002-11-01
HUP9903855A3 (en) 2000-06-28
NO991613L (no) 1999-04-06
US20020001598A1 (en) 2002-01-03
AR013613A1 (es) 2001-01-10
HK1021939A1 (en) 2000-07-21
EG24070A (en) 2008-05-11
HRP970537B1 (en) 2002-08-31
AU731235B2 (en) 2001-03-29
UY24738A1 (es) 2001-05-31
WO1998015268A1 (fr) 1998-04-16
KR100334687B1 (ko) 2002-04-27
CA2267096A1 (fr) 1998-04-16
IS1985B (is) 2005-02-15
IL128745A0 (en) 2000-01-31
TR199900789T2 (xx) 1999-07-21
US8535721B2 (en) 2013-09-17
DZ2316A1 (fr) 2002-12-28
DK0956010T3 (da) 2002-08-12
JP3523270B2 (ja) 2004-04-26
FR2754177B1 (fr) 1999-08-06
EP0956010B1 (de) 2002-04-17
SI0956010T1 (en) 2002-10-31
IL128745A (en) 2004-05-12
CO4900080A1 (es) 2000-03-27
EP0956010A1 (de) 1999-11-17
FR2754177A1 (fr) 1998-04-10
CN1232391A (zh) 1999-10-20
PL332249A1 (en) 1999-08-30
EE03744B1 (et) 2002-06-17
RS49602B (sr) 2007-06-04
AU4560297A (en) 1998-05-05
ATE216228T1 (de) 2002-05-15

Similar Documents

Publication Publication Date Title
ATE216228T1 (de) Valproinsäure enthaltende mikrosphären für orale verabreichung
NO950785D0 (no) Fettsyrederivater
DE69703385D1 (de) Alkoxyessigsäure-derivate
NO990821D0 (no) Arylsulfonylamino-hydroksaminsyre-derivater
IL116673A (en) Stable oral pharmaceutical composition containing an acid labile benzimidazole
DE59506139D1 (de) Orale Retard-Präparation
ATE211131T1 (de) Arylsulfonylaminohydroxamsäurederivate
ATE248812T1 (de) Arylsulfonylhydroxamsäurederivate
DK1003720T3 (da) Aryloxyarylsulfonylaminohydroxamsyrederivater
DE69518331D1 (de) Orale zubereitungen
ATE239005T1 (de) (4-sulfonylamino)-tetrahydropyran-4-carbonsäure hydroxamiden
NO934726D0 (no) (S)(+)-2-etoksy-4-ÚN-Ú1-(2-piperidinofenyl)-3-metyl-1-butyl¾amin okarbonylmetyl¾-benzoesyre
NO20006115L (no) Nytt 3-aryl-2-hydroksypropionsyrederivat (I)
ATE210720T1 (de) Verdickte saure zusammensetzung
NO953367L (no) Anvendelse av substituerte 4-fenyl-6-amino-nikotinsyre-derivater som legemidler
DE68903858D1 (de) Orale mittel fuer wiederkaeuer.
DE3852599D1 (de) Orale Zusammensetzungen.
DE3688182D1 (de) Orale zusammensetzung.
ATE230734T1 (de) 3-alkoxyisoxazol-4-yl-substituierte 2- aminocarbonsäurederivate
DE69432149D1 (de) Orale Zubereitungen
DE69708130D1 (de) A-oxo-butansäuren enthaltende pharmazeutische zusammensetzung
DE59707658D1 (de) Glyoxylsäure-derivate
DE69300492D1 (de) Orale Zusammensetzung.
ITMI950961A0 (it) Composizioni farmaceutiche contenenti gemfibrozil
EE04061B1 (et) Metüleenbisfosfoonhappe derivaadid

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SANOFI-AVENTIS, PARIS, FR

R082 Change of representative

Ref document number: 956010

Country of ref document: EP

Representative=s name: TER MEER STEINMEISTER & PARTNER GBR PATENTANWA, DE